表面增强激光解吸/离子化质谱蛋白质芯片技术在筛选肾癌患者尿液标记物中的应用

目的 用表面增强激光解吸／离子化-飞行时间质谱(SEDLI-TOF-MS)蛋白质芯片技术筛选肾癌患者尿液相对特异标记物。方法 肾癌组40例,均经手术病理和／或临床影像证实;正常人群组40名,非肾癌其他泌尿系疾病组40例,二组合并为对照组。用IMAC-Cu-3芯片检测各尿液标本。结果 将肾癌组与对照组尿液标本结果相比较,发现肾癌差异明显的潜在标记物4个,相对分子量分别为4020、4637、5070、5500,分别以2．0、5．0、5．0、5．0为界值时,其诊断肾癌的敏感性为57．5％、66．7％、63．7％、65％,特异性为86．2％、95％、82．5％、75％;其中4637、5070差异表达蛋白质在对照组中高表达,肾癌组中低表达;而4020、5500差异表达蛋白质在肾癌组中高表达,对照组中低表达。结论 SELDI-TOF-MS蛋白质芯片技术是一种快速、简便易行、用量少和高通量分析方法,不仅能直接筛选出肾癌患者尿液中相对特异的潜在标记物,而且具有较好的临床应用价值。

Screening urine markers of renal cell carcinoma using SELDI-TOF-MS

Objective To screen relatively specifical markers in urines from renal cell carcinoma patients using surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) ProteinChip technology. Methods Urine samples from 40 renal cell carcinoma (RCC) patients, 40 healthy volunteers and 40 patients with other urogenital diseases were analyzed using IMAC-Cu-3 PoteinChip, which can specifically bind the metal-combining-proteins. Proteomic spectra were generated by mass spectrometry. Results Four differentially expressed potentially biomarkers were identified with the relative molecular weights of 4020, 4637, 5070, and 5500. The sensitivity for diagnosing RCC was 57.5%, 66.7%, 63.7%, 65%, and specificity was 86.2%, 95%, 82.5% and 75% when the critical points were 2.0,5.0,5.0 and 5.0 respectively. Conclusions SELDI-TOF-MS ProteinChip technology is a quickly, easy and convenient, and high-throughput analyzing method capable of screening several relatively specific, potential biomarkers from the urines of RCC patients and had better clinical value.